Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
830 stopped studies mapped to Genitourinary System Carcinoma and descendants · 90% state a reason
Over the 830 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT01547676 | Clamped or Unclamped Surgery in Treating Patients With Kidney Cancer | N/A | terminated | Mar 8, 2012 | University of Southern California | P.I. decided to terminate study due to multiple unresolved issues | Other (stated, no rule matched) |
| NCT00659399 | Feasibility Study of Short Term Fondaparinux (Arixtra) in Chemotherapy-Pretreated Ovarian… | Phase 1 | withdrawn | Apr 16, 2008 | NYU Langone Health | Low accrual | Enrollment / accrual |
| NCT00058214 | Perifosine in Treating Patients With Recurrent Prostate Cancer | Phase 2 | terminated | Apr 9, 2003 | National Cancer Institute (NCI) | Did not meet interim stopping criteria for continuation to the second stage. | Other (stated, no rule matched) |
| NCT01720693 | Novel Controlled Hypo-Perfusion Technique in Partial Nephrectomy | Phase 2 | terminated | Nov 2, 2012 | University Health Network, Toronto | Low accrual | Enrollment / accrual |
| NCT01353794 | Study to Observe Safety and Efficacy of Nexavar in Treatment of Kidney Cancer(POWER-NEXT) | — | withdrawn | May 16, 2011 | Bayer | not stated | Not stated |
| NCT00312650 | Doxil and Gemcitabine in Recurrent Ovarian Cancer | Phase 2 | terminated | Apr 10, 2006 | Women and Infants Hospital of Rhode Island | not stated | Not stated |
| NCT01492920 | Acetyl-L-Carnitine Hydrochloride in Preventing Peripheral Neuropathy in Patients With… | Phase 3 | withdrawn | Dec 15, 2011 | Gynecologic Oncology Group | Withdrawn | Other (stated, no rule matched) |
| NCT00352859 | Phase IV Randomization to On-Going Treatment to Evaluate Sustained Sorafenib | Phase 4 | terminated | Jul 17, 2006 | Bayer | not stated | Not stated |
| NCT00072137 | Neoadjuvant Intravesical Vaccine Therapy in Treating Patients With Bladder Carcinoma Who… | Phase 1 | terminated | Nov 6, 2003 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT01927393 | Palliative Care in Improving Quality of Life and Symptoms in Patients With Stage III-IV… | N/A | withdrawn | Aug 22, 2013 | City of Hope Medical Center | Study was not funded | Funding |
| NCT00622479 | Mechanistic Evaluation on Sorafenib Induced Hypophosphatemia. | Phase 1 | terminated | Feb 25, 2008 | Bayer | not stated | Not stated |
| NCT00678288 | A Study to Assess Sorafenib Alone and in Combination With Low-Dose Interferon Following… | Phase 2 | terminated | May 15, 2008 | Bayer | not stated | Not stated |
| NCT01838265 | Trial of Prostate Cancer Patients Undergoing Active Surveillance With or Without…(MGM) | — | withdrawn | Apr 24, 2013 | University of Miami | Unlikely to Accrue | Enrollment / accrual |
| NCT01020305 | Temsirolimus to Reverse Androgen Insensitivity for Castration-resistant Prostate Cancer | Phase 1 / Phase 2 | terminated | Nov 25, 2009 | Sandy Srinivas | Decision by funding sponsor due to poor accrual | Enrollment / accrual |
| NCT01095367 | Seprafilm™ for the Prevention of Intraperitoneal Adhesions and Improved Delivery of… | N/A | terminated | Mar 30, 2010 | University of British Columbia | due to company changes and lack of funding-unlikely to have sufficient numbers to analyze… | Funding |
| NCT01943058 | Megestrol Acetate or Levonorgestrel-Releasing Intrauterine System in Treating Patients… | Phase 2 | withdrawn | Sep 16, 2013 | University of Southern California | Lack of funding | Funding |
| NCT00001703 | Vaccine Therapy With Tumor Specific Mutated VHL Peptides in Adult Cancer Patients With… | Phase 2 | terminated | Nov 4, 1999 | National Cancer Institute (NCI) | Due to poor accrual and lack of peptide vaccine | Enrollment / accrual |
| NCT02054793 | Phase Ib/II Study Evaluating Orteronel (Without Prednisone) Combined With Itraconazole In… | Phase 1 / Phase 2 | withdrawn | Feb 4, 2014 | Emmanuel Antonarakis, MD | This study was never able to open due to lack of funding from the pharmaceutical company. | Funding |
| NCT01793636 | A Study Comparing AZD2014 vs Everolimus in Patients With Metastatic Renal Cancer(ZEBRA) | Phase 2 | terminated | Feb 15, 2013 | Queen Mary University of London | Inferior efficacy of study drug in renal indication. | Efficacy / futility |
| NCT00112905 | Sorafenib in Treating Patients With Regional or Metastatic Cancer of the Urothelium | Phase 2 | terminated | Jun 3, 2005 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00835679 | Cetuximab and/or Dasatinib in Patients With Colorectal Cancer and Liver Metastases That… | Early Phase 1 | terminated | Feb 4, 2009 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00303862 | AZD2171 in Treating Patients With Refractory Metastatic Kidney Cancer | Phase 2 | terminated | Mar 17, 2006 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00684996 | Bevacizumab With or Without MEDI-522 in Treating Patients With Unresectable or Metastatic… | Phase 1 / Phase 2 | terminated | May 28, 2008 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT01907308 | Trebananib (AMG 386) in Combination With Docetaxel for Advanced Urothelial Carcinoma | Phase 2 | withdrawn | Jul 24, 2013 | University of Colorado, Denver | Sponsor's decision to terminate the study | Sponsor / business decision |
| NCT01233505 | Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors | Phase 1 | terminated | Nov 3, 2010 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00523640 | A Phase II Trial of Gemcitabine, Capecitabine, and Bevacizumab in Metastatic Renal Cell… | Phase 2 | terminated | Aug 31, 2007 | University of Chicago | Too slow accrual | Enrollment / accrual |
| NCT00942058 | Serum CA9 Level as Biological Marker of the Treatment Response in Metastatic Renal Cell…(CA9CRM) | — | terminated | Jul 20, 2009 | Centre Hospitalier Universitaire de Saint Etienne | Difficult for recruiting | Enrollment / accrual |
| NCT01677390 | A Phase 1b Study of SGN-75 in Combination With Everolimus in Patients With Renal Cell… | Phase 1 | terminated | Sep 3, 2012 | Seagen Inc. | not stated | Not stated |
| NCT01403103 | Cholecalciferol(25-[OH]-Vitamin D) in Treating Patients With Colorectal Cancer | Early Phase 1 | withdrawn | Jul 27, 2011 | Case Comprehensive Cancer Center | Slow Accrual | Enrollment / accrual |
| NCT01202890 | Study of Revlimid With Doxil and Avastin for Patients With Platinum Resistant Ovarian… | Phase 1 | terminated | Sep 16, 2010 | New Mexico Cancer Research Alliance | Terminated due to inadequate rate of accrual. | Enrollment / accrual |
| NCT01982487 | Vaccine Therapy and IDO1 Inhibitor INCB024360 in Treating Patients With Epithelial… | Phase 1 / Phase 2 | withdrawn | Nov 13, 2013 | Roswell Park Cancer Institute | not stated | Not stated |
| NCT01063998 | A Urinary Tumor Marker (Kidney Injury Molecule-1) for the Detection of Renal Cell… | — | terminated | Feb 5, 2010 | Jason Hafron | Preliminary data did not show expected outcomes. | Other (stated, no rule matched) |
| NCT00110344 | Research Study for Patients With Metastatic Renal Cell Carcinoma | Phase 2 | terminated | May 9, 2005 | Bayer | not stated | Not stated |
| NCT00203866 | Trial of G250 Peptide and IL-2 Following Surgical Resection of Locally… | Phase 2 | terminated | Sep 20, 2005 | University of Chicago | Study completed | Other (stated, no rule matched) |
| NCT00942838 | Whole Abdomen Radiation in Conjunction With Intraperitoneal Chemotherapy for the…(WAR) | Phase 1 | withdrawn | Jul 21, 2009 | University of Utah | PI decision due to under accrual. | Enrollment / accrual |
| NCT00557830 | Randomized Study of Sorafenib Dose Escalation in Patients With Previously Untreated… | Phase 2 | terminated | Nov 14, 2007 | Accelerated Community Oncology Research Network | The study was closed to enrollment when it became clear that enrollment was too slow to complete… | Enrollment / accrual |
| NCT00003517 | Antineoplaston Therapy in Treating Patients With Stage III or Stage IV Prostate Cancer | Phase 2 | withdrawn | Jan 27, 2003 | Burzynski Research Institute | not stated | Not stated |
| NCT00040989 | BAY 56-3722 in Treating Patients With Recurrent, Unresectable, or Metastatic Kidney Cancer | Phase 2 | withdrawn | Jan 27, 2003 | Jonsson Comprehensive Cancer Center | not stated | Not stated |
| NCT01073644 | Post Marketing Surveillance On The Safety And Tolerability Of Sunitinib Malate (Sutent)… | — | terminated | Feb 23, 2010 | Pfizer | The study was prematurely discontinued due to poor recruitment on 18th April 2013. There were no… | Safety / toxicity |
| NCT00098618 | Sorafenib and Interferon Alfa in Treating Patients With Locally Advanced or Metastatic… | Phase 2 | terminated | Dec 8, 2004 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT01834183 | Tivozanib + Gemcitabine in Metastatic RCC | Phase 2 | withdrawn | Apr 17, 2013 | Dana-Farber Cancer Institute | Sponsor Aveo has withdrawn support for this trial. | Other (stated, no rule matched) |
| NCT00004856 | Trastuzumab in Treating Patients With Previously Treated, Locally Advanced, or Metastatic… | Phase 2 | terminated | Sep 30, 2003 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT01781442 | A Post Marketing Surveillance As Required By Philippine Food And Drug Administration | — | withdrawn | Feb 1, 2013 | Pfizer | not stated | Not stated |
| NCT00491075 | Pemetrexed Plus Gemcitabine in Renal Cell Cancer | Phase 2 | terminated | Jun 25, 2007 | M.D. Anderson Cancer Center | Closed early for poor accrual. | Enrollment / accrual |
| NCT01466504 | Effect of Sorafenib or Regorafenib on P63 Expression and Keratinocyte Differentiation in… | — | terminated | Nov 8, 2011 | Dartmouth-Hitchcock Medical Center | Accrual did not meet expectations. Over nearly 2 years just 4 subjects were treated on study. The… | Enrollment / accrual |
| NCT01616186 | Everolimus/Sorafenib or Sunitinib in Patients With Metastatic Renal Cell Carcinoma (RCC) | Phase 2 | withdrawn | Jun 11, 2012 | Andrea Harzstark | not stated | Not stated |
| NCT00091195 | Depsipeptide (Romidepsin) in Treating Patients With Recurrent Ovarian Epithelial or… | Phase 2 | terminated | Sep 9, 2004 | National Cancer Institute (NCI) | Administratively complete. | Other (stated, no rule matched) |
| NCT00937482 | Cediranib Maleate and Whole Brain Radiation Therapy in Patients With Brain Metastases… | Phase 1 | terminated | Jul 13, 2009 | National Cancer Institute (NCI) | Administratively complete. | Other (stated, no rule matched) |
| NCT00429026 | Conditioning Regimen in Nonmyeloablative Allogeneic Hematopoietic Stem Cell… | Phase 2 | terminated | Jan 31, 2007 | M.D. Anderson Cancer Center | Slow accrual, study terminated. | Enrollment / accrual |
| NCT00601120 | RF Ablation of Treatment of Metastatic Lesions in Patients Undergoing Antiangiogenic… | N/A | withdrawn | Jan 25, 2008 | Beth Israel Deaconess Medical Center | This protocol was never officially opened and no patients were recruited. | Enrollment / accrual |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Mar 27, 2015source: clinicaltrials